dc.contributor.author | Brody, LP | |
dc.contributor.author | Sahuri-Arisoylu, M | |
dc.contributor.author | Parkinson, JR | |
dc.contributor.author | Parkes, HG | |
dc.contributor.author | So, PW | |
dc.contributor.author | Hajji, N | |
dc.contributor.author | Thomas, EL | |
dc.contributor.author | Frost, GS | |
dc.contributor.author | Miller, AD | |
dc.contributor.author | Bell, JD | |
dc.date.accessioned | 2017-10-03T14:25:12Z | |
dc.date.issued | 2017-01-01 | |
dc.identifier.citation | International journal of nanomedicine, 2017, 12 pp. 6677 - 6685 | |
dc.identifier.issn | 1176-9114 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/846 | |
dc.identifier.eissn | 1178-2013 | |
dc.identifier.doi | 10.2147/ijn.s135968 | |
dc.description.abstract | Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system - liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 6677 - 6685 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | DOVE MEDICAL PRESS LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | HCT116 Cells | |
dc.subject | HT29 Cells | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Colonic Neoplasms | |
dc.subject | Cations | |
dc.subject | Acetates | |
dc.subject | Histone Deacetylases | |
dc.subject | Lipids | |
dc.subject | Antineoplastic Agents | |
dc.subject | Liposomes | |
dc.subject | Xenograft Model Antitumor Assays | |
dc.subject | Nanoparticles | |
dc.title | Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2147/ijn.s135968 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2017-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | International journal of nanomedicine | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.publication-status | Published | |
pubs.volume | 12 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Magnetic Resonance | |
dc.contributor.icrauthor | Parkes, Harold | |